Nov 8, 2022 | health policy, oncopolicy |
this article was originally published on the macdonald laurier laurier institute blog by W. Neil Palmer on November 1.2022 and republished here. The Patented Medicine Prices Review Board (PMPRB) is once again attracting the ire of the life sciences industry and...
